Ask a doctor about a prescription for MINIMS PHENYLEPHRINE HYDROCHLORIDE 100 mg/mL EYE DROPS SOLUTION
Package Leaflet: Information for the Patient
Minims®Fenilefrine Hydrochloride 100mg/mlEye Drops Solution
Fenilefrine Hydrochloride
Read the entire package leaflet carefully before starting to use this medication, as it contains important information for you.
Keep this package leaflet, as you may need to read it again. If you have any questions, consult your doctor or pharmacist.
This medication has been prescribed to you only, and you should not give it to others, even if they have the same symptoms as you, as it may harm them.
If you experience side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. See section 4.
Contents of the Package Leaflet
Minims Fenilefrine Hydrochloride 100 mg/ml contains Fenilefrine Hydrochloride, an active substance used to dilate the pupil of your eye.
This eye drop is used to dilate the pupil (mydriasis) for an eye examination or during eye surgery.
Do not use Minims Fenilefrine Hydrochloride Eye Drops:
Warnings and Precautions
Talk to your doctor or pharmacist before using Minims Fenilefrine Hydrochloride.
Other Medications and Minims Fenilefrine Hydrochloride
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medications.
Pregnancy, Breastfeeding, and Fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
There is limited or no information on the use of fenilefrine in pregnant or breastfeeding women. This medication should not be used during pregnancy or breastfeeding unless absolutely necessary.
No reproductive animal studies have been conducted with topical fenilefrine.
Driving and Using Machines
Due to the effect on vision (pupil dilation), the use may have adverse effects on the ability to drive and use machines. Do not drive vehicles or operate machinery until your vision is normal.
Follow exactly the administration instructions of this medication indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
The recommended dose is 1, 2, or 3 instillations every few minutes.
Minims Fenilefrine Hydrochloride is designed for single use and should be discarded immediately after use.
Do not touch the eye with the tip of the Minims Fenilefrine Hydrochloride container.
After administration of the eye drop, the following measures should be taken to reduce systemic absorption:
If You Use More Minims Fenilefrine Hydrochloride Than You Should.
In the case of an ocular overdose, the dilation of the pupil can be easily and quickly eliminated by a miotic.
Accidental oral ingestion may cause side effects such as headache, palpitations, and hypertension.
These effects should be treated symptomatically.
In the case of a fenilefrine overdose, a severe toxic reaction can occur rapidly, but it will be short-lived. Therefore, the treatment is mainly symptomatic. Immediate injection of a rapid-acting alpha-adrenergic blocking agent such as phentolamine (2-5 mg, IV) is recommended.
In case of overdose, consult your doctor, pharmacist, or call the Toxicology Information Service, phone: 91 562 04 20.
If You Forget to Use Minims Fenilefrine Hydrochloride.
Do not take a double dose to make up for a forgotten dose.
If you have any doubts about the use of this medication, consult your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them.
The following side effects have been reported:
Ocular Effects
Allergic symptoms such as conjunctivitis and keratitis, with redness, burning, itching, and photophobia may occur. If such symptoms occur, treatment should be discontinued. Pupil constriction (miosis) may occur after stopping treatment.
Systemic Effects
In the case of frequent and prolonged administration, blood absorption is possible, and the following adverse effects may occur: headache, palpitations, hypertension, rapid heartbeat, difficulty breathing (shortness of breath), dizziness. Serious cardiovascular reactions, including coronary artery spasms, cardiac arrhythmias, and infarction, have been reported after the topical use of fenilefrine hydrochloride 100 mg/ml solution. In patients with pre-existing cardiovascular disease, these reactions were sometimes fatal.
Additional Side Effects in Children:Unknown frequency (cannot be estimated from available data) fluid or swelling in the lungs
Reporting Side Effects
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Store at temperatures below 25°C in the original package to protect it from light.
Do not use this medication after the expiration date stated on the box after "EXP". The expiration date is the last day of the month indicated.
Medications should not be disposed of through wastewater or household waste. Deposit the containers and medications you no longer need at the SIGRE collection point in your pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medications you no longer need. This will help protect the environment.
Composition of Minims Fenilefrine Hydrochloride
Appearance of the Product and Package Contents
MINIMS containers and polypropylene cap, containing 0.5 ml of solution. Each MINIMS is packaged in a polypropylene bag. Boxes of 5 and 20 MINIMS.
Not all package sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
BAUSCH + LOMB IRELAND LIMITED
3013 Lake Drive
Citywest Business Campus
Dublin 24, D24PPT3
Ireland
Manufacturer:
Laboratoire Chauvin
Z.I.Ripotier
07200 Aubenas – France
You can request more information about this medication by contacting the local representative of the marketing authorization holder.
Local Representative in Spain
Bausch & Lomb S.A.
Avda. Valdelaparra, nº 4 28108 Alcobendas
Madrid
Tel: 91 – 657 63 00
Date of the Last Revision of this Package Leaflet:September/2024
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for MINIMS PHENYLEPHRINE HYDROCHLORIDE 100 mg/mL EYE DROPS SOLUTION – subject to medical assessment and local rules.